ArticleJournal of diabetes and metabolic disorders2020
Cymene consumption and physical activity effect in Alzheimer's disease model: an in vivo and in vitro study.
Article in Journal of diabetes and metabolic disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 16 citations in OpenAlex.
- Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025Review
- Neuroprotective Effects of Thymol and p-Cymene in Immobilized Male rats through Alterations in Molecular, Biochemical, Histological, and Behavioral Parameters.Neurochemical research · 2024Article
- The effects of carvacrol and p-cymene on AβCNS neuroscience & therapeutics · 2024Article
- Anti-Cholinesterase and Anti-α-Amylase Activities and Neuroprotective Effects of Carvacrol andInternational journal of molecular sciences · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlzheimer's disease (AD) is one of the most important neurodegenerative diseases and accompanied by the production of free radicals and inflammatory factors. Studies have shown that p-cymene has anti-inflammatory and anti-oxidant effects. Here, the effects of this compound were investigated on a rat model of AD.
methodsIn order to create Alzheimer's rat model, bilateral injection of Amyloid β1-42 (Aβ1-42) into rats hippocampus was performed. Both therapeutic (post-AD induction) and preventive effects of p-cymene consumption with doses of 50 and 100 mg/kg were investigated. In addition, the effects of adding short-term exercise to the process were also observed. In vitro, Aβ1-42 peptide was driven toward fibril formation and effect of p-cymene was observed on the resulting fibrils.
resultsLearning and memory indices in the AD rats were significantly reduced compared to the Sham group, while p-cymene consumption with both doses, as well as performing exercise counteracted AD consequences. Moreover, increased neurogenesis and reduced amyloid plaques counts were observed in treated rats. In vitro formed fibrils of Aβ1-42 were partially disaggregated in the presence of p-cymene. DISCUSSION: p-Cymene could act on this AD model via antioxidant and anti-inflammatory properties as well as direct anti-fibril effect.
conclusionp-cymene can improve AD-related disorders including memory impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.